Thyroid disease

Discontinuation of Levothyroxine in Adults Aged 60 Years or Older

JAMAPublished Prospective single-group study

Authors' conclusion

In this open-label, single-group prospective study, 25.7% of adults aged 60 years or older discontinued levothyroxine treatment while maintaining adequate thyroid function at 1 year. Evaluation of the need to continue levothyroxine should be considered in adults aged 60 years or older, particularly in those taking a dose of 50 µg/d or lower.

Study context

Population
Community-dwelling adults aged ≥60 years on stable LT4 (≤150 µg/d) for ≥1 year with TSH <10 mIU/L, 58 general practices in the Netherlands; median age 70 years, 80% female366 completed follow-up
Participants
370 adults
Outcome
Proportion who discontinued LT4 with TSH <10 mIU/L and FT4 within reference range
Follow-up
1 year after start of discontinuation
Methodological detailsopen-label, protocol-driven stepwise dose reduction, 58 general practices, Enrolled January 2020–July 2022; final follow-up December 12, 2023
  • Open-label
  • Protocol-driven stepwise dose reduction
  • 58 general practices
  • Enrolled January 2020–July 2022; final follow-up December 12, 2023

Main finding

As reported in the abstract

Successful LT4 discontinuation · 1 year

LT4 discontinuation

25.7%

95 of 370

Observational data: associations, not effects.

Secondary outcomes

Thyroid function in those who successfully discontinued · 1 year

Median TSH (range 1.56-9.40 mIU/L)
5.03 mIU/L
Mean FT4 (range 0.80-1.43 ng/dL)
1.01 ng/dL
TSH <4.8 mIU/L among successful discontinuers
46 (48.4%) (95% CI 38.6%-58.3%)

Successful discontinuation in subgroup on LT4 dose ≤50 µg/d · 1 year

Successfully discontinued, of 88 participants on ≤50 µg/d
56 (63.6%)

Thyroid-related quality of life · baseline to 1 year

No clinically relevant changes overall or stratified by successful vs unsuccessful discontinuation

Original publication

Discontinuation of Levothyroxine in Adults Aged 60 Years or Older. JAMA. Published 6 April 2026. doi:10.1001/jama.2026.2864

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.